ORGANIZING SECRETARIAT:
Nadirex International  
+39.0382.525714  
chiara.zoncada@nadirex.com
annalisa.antonino@nadirex.com
Hotel Monaco & Grand Canal, Venice

TOP 5 IN INFECTIOUS DISEASE

Innovation. This is the word that inspires the TOP5 Congress in Venice. This event is organized to find new solutions for different challenges in infectious diseases and to bring current global issues to the attention of institutions. Nowadays, in the era of globalization, innovation in infectious diseases is crucial to find new weapons against several threats. The challenges in the treatment of infectious diseases will be discussed in a scientific and public debates. The following topics will be covered:

1. Antimicrobial resistant microrganisms. The global spread of multidrug resistant organisms (MDRO) causing severe infections in both the community and nosocomial setting is a threat for public health. Innovative strategies are needed to implement early diagnosis and optimal/appropriate use of new available antibiotics.

2. COVID-19 is not over and frail patients continued to be at increased risk of severe outcomes subsequent to SARS CoV-2 infection. Implementation of new strategies (monoclonal antibodies, vaccines, antivirals) is crucial to prevent and treat COVID-19. New vaccine platforms represent innovative strategies that should be appropriately applied to the clinical setting.

3. HIV still represents an ongoing challenge. Increase in late presentation of HIV infection poses the scientific community in front of the need for implementation of pre-exposure prophylaxis, testing and early HIV infection diagnosis. Moreover, the complexity of HIV-positive people highlights the need for tailored therapeutic approaches.

4. Beyond the ambitious goal of HCV eradication, emergence of delta virus as cause of hepatitis and presence of coinfections (such as HIV and HBV) poses new challenges that should be addressed.

5. Fungi are evolving and new multidrug resistant species spread around the world. New antifungals are needed to overcome resistance in yeast and molds infections.

But what does “innovation” mean in these 5 field of Infectious Diseases? Innovation means “appropriate and rational use” of diagnostic methods, antimicrobials, Big Data and maching learning finalized to develop updated knowledge and new solutions for the treatment of Infectious Diseases in the modern era. These issues should be discussed with academicians, stakeholders, professionals and young researchers to share experiences and evidences and to have an unforgettable experience in Venice.

SCIENTIFIC SECRETARIAT

PRESIDENT
Prof. Marco Falcone

Professor of Infectious Diseases
Department of Clinical and Experimental Medicine - University of Pisa
Azienda Ospedaliero-Universitaria Pisana - Pisa (Italy)

Prof.ssa Annamaria Cattelan

Direttore Unità Op. Complessa Malattie Infettive e Tropicali, Az. Ospedaliera di Padova - Padova

Prof.ssa Cristina Mussini

Professore Ordinario di Malattie Infettive
Direttore della Clinica delle Malattie Infettive e Tropicali, Università di Modena e Reggio Emilia
Azienda Ospedaliero-Universitaria Policlinico di Modena

Dr.ssa Giusy Tiseo

Dirigente Medico in Malattie Infettive, Azienda Ospedaliero Universitaria Pisana – Pisa

Dr. Sandro Panese

Direttore dell'Unità Operativa di Malattie Infettive, Azienda Ulss 3 Serenissima – Mestre (VE)

PATRONAGE

SPONSOR

ORGANIZING SECRETARIAT

Nadirex International S.r.l.

Provider ECM n.265

Via Riviera 39,27100 Pavia (PV)
P.IVA e C.F. 12521390158

Phone: +39.0382.525714
Website: www.nadirex.com

Dott.ssa Chiara Martina Zoncada
chiara.zoncada@nadirex.com

Dott.ssa Annalisa Antonino
annalisa.antonino@nadirex.com

Nadirex International S.r.l.
Via Riviera 39, 27100 Pavia (PV) - Telefono: +39.0382.525714 - Fax: +39.0382.525736
P.IVA e C.F. 12521390158 - Reg. Imprese uff. Pavia 12521390158 - REA 233496 - Capitale Sociale €10.500 i.v.
Certificazione UNI EN ISO 9001 - Provider ECM n.265
Privacy policy